11/6/2019 7:06:05 AM
Regeneron, Vyriad Announce Strategic Agreement For Development Of New Oncolytic Virus Treatments For Cancer
11/5/2019 6:43:00 AM
Regeneron Updates On Phase 3 Libtayo Development Program In Advanced Non-small Cell Lung Cancer
11/5/2019 6:37:50 AM
Regeneron Pharmaceuticals (REGN) Announces $1 Bln Stock Buyback
11/5/2019 6:31:30 AM
Regeneron Q3 GAAP EPS $5.86; Non-GAAP Diluted EPS $6.67
10/29/2019 8:21:42 AM
Regeneron Pharma And Sanofi: EC Approves New Indication For Dupixent In Chronic Rhinosinusitis With Nasal Polyposis
9/20/2019 7:00:41 AM
The Lancet Publishes Results From 2 Positive Phase 3 Trials Of Dupixent In Chronic Rhinosinusitis With Nasal Polyps
9/20/2019 6:46:39 AM
Regeneron: EMA's CHMP Adopts Positive Opinion For Dupixent In Third Indication
8/14/2019 7:01:23 AM
Regeneron Announces Positive Topline Results From Phase 3 Trial Of Evinacumab